Departament de Farmacologia, Facultat de Farmàcia, Universitat de València, Av. Vicent Andrés Estellés s/n, 46100-Burjassot, Valencia, Spain.
Curr Med Chem. 2013;20(23):2892-8. doi: 10.2174/09298673113209990008.
Shikonin is the major constituent of the root of Lithospermum erythrorhizon, which has been used in traditional Chinese medicine to treat external wounds, burns, or dermatitis for centuries. Nowadays, this root is commonly used as an herbal medicine against cancer. Studies carried out over the past 30 years have demonstrated that many of the effects historically associated with the use of this root have a scientific basis, with shikonin and its derivatives being responsible for its pharmacological properties. These include both anti-inflammatory and anticancer effects. While previous summaries have focused on the pharmacokinetics and toxicity of shikonin, the aim of this review is to report on the most current findings with regard to shikonin's antitumor activity by summarizing and comparing the various studies published in the last ten years and discussing the pharmacological aspects that make shikonin a promising anticancer agent.
紫草素是紫草的主要成分,紫草在传统中药中已被用于治疗外伤、烧伤或皮炎数百年。如今,这种根通常被用作治疗癌症的草药。过去 30 年的研究表明,许多与使用这种根相关的历史效应都有科学依据,紫草素及其衍生物是其药理特性的原因。这些包括抗炎和抗癌作用。虽然以前的综述集中在紫草素的药代动力学和毒性上,但本综述的目的是通过总结和比较过去十年发表的各种研究报告,报告紫草素抗肿瘤活性的最新发现,并讨论使紫草素成为一种有前途的抗癌药物的药理学方面。